Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case...

Area of Science:

• Neurology
• Immunology
• Multiple Sclerosis Therapeutics

Background:

• Cladribine is an effective pulsed immune reconstitution therapy for relapsing-remitting multiple sclerosis (MS).
• Severe disease reactivation early after cladribine treatment poses a clinical challenge due to limited management guidelines.

Observation:

• A case study details a patient with significant MS disease activity within the first year of cladribine treatment.
• The patient was subsequently treated with alemtuzumab, resulting in sequential immune reconstitution therapy.

Findings:

• This sequential approach achieved good control of MS disease activity.
• However, the patient experienced several serious infectious complications.

Implications:

• Sequential immune reconstitution therapies may offer efficacy in managing aggressive MS.
• This strategy carries a notable increased risk of serious infections, requiring careful monitoring.